AbbVie’s Gonzalez Outlines CEO Succession Process

Humira Erosion Follows Projections

02 Feb 2024

AbbVie may look to an internal successor to Rick Gonzalez once he is satisfied the company is back on a growth trajectory. Skyrizi and Rinvoq continue meteoric growth, with increased sales projections.

AbbVie Building — AbbVie outlined its succession strategy for CEO Rick Gonzalez • Source: Shutterstock (Valeriya Zankovych/Shutterstock)

With AbbVie Inc. not quite a year into US biosimilar competition to top-seller Humira, some shareholders’ thoughts apparently are turning to what is next for the large pharma, especially since the revenue paths for Humira post-US patent expiration and its successors Skyrizi and Rinvoq are in line or better than what was expected. Chairman and CEO Rick Gonzalez discussed succession plans for the top spot during AbbVie’s fourth quarter and full year 2023 sales and earnings call on 2 February.

Previously, Gonzalez had said he would recommend transitioning to his successor once AbbVie had navigated through the worst of Humira’s (adalimumab) loss of exclusivity and when the company appeared on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

28 May 2025

• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

26 May 2025

• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.